Vienna, 5 September 2017 – Savira pharmaceuticals GmbH recently signed a license agreement with Roche.
Under the terms of the agreement, Savira will receive a non-disclosed one-time payment in return for a non-exclusive, world-wide license to a part of Savira’s influenza polymerase patent rights.
The agreement relates to a previous collaboration between Roche and Savira, which was terminated recently.
Savira pharmaceuticals GmbH – based in Vienna, Austria – is focusing on the design of novel, innovative influenza therapeutics using a rational, structure-based drug development approach. Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.
Savira is an EMBL spin-off company